首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Association between Interleukin-6 Promoter Polymorphism (-174 G/C) Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
【2h】

Association between Interleukin-6 Promoter Polymorphism (-174 G/C) Serum Interleukin-6 Levels and Mortality in Severe Septic Patients

机译:重度脓毒症患者白细胞介素6启动子多态性(-174 G / C)血清白细胞介素6水平与死亡率之间的关联

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074−1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days.
机译:脓毒症患者中白介素(IL)-6启动子多态性(-174 G / C),循环IL-6水平与死亡率之间的关联几乎未得到解决,然后仅在小样本量研究中与它们之间存在直接关联以前没有报告。因此,我们研究的目的是确定这种关联是否存在。进行了一项包括重度脓毒症患者在内的观察,前瞻性和多中心研究,并确定了严重脓毒症诊断时的血清IL-6水平和IL-6启动子多态性(-174 G / C)。研究的终点是30天死亡率。该研究纳入263名具有以下IL-6启动子多态性(-174 G / C)基因型的患者:123(46.8%)GG,110(41.8%)GC和30(11.4%)CC。与其他基因型(GC或GG)相比,CC纯合子患者在30天时表现出较低的败血症相关器官衰竭评估(SOFA)评分,血清IL-6水平和死亡率。在回归分析中,CC纯合子患者的30天死亡率低于基因型GG(优势比= 0.21; 95%CI = 0.053-0.838; p = 0.03)或GC(风险比= 0.28; 95%CI = 0.074-) 1.037; p = 0.06)。我们研究的最重要结果是,对于脓毒症患者,CC可能是一种有利的基因型,表现出较低的血清IL-6水平和30天内死亡的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号